Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that preclinical data for PROTAC BCL6 degrader ...
Two presentations, including one oral session, build on existing data and show deep and durable clinical remission rates, combined with a strong safety profile, for SENTI-202 in treating ...
An update from Nanjing Leads Biolabs Co., Ltd. Class H ( ($HK:9887) ) is now available. Nanjing Leads Biolabs Co., Ltd. announced that five of its ...
SUMMIT data for bezuclastinib in NonAdvSM selected for two oral presentations which will describe its best-in-class potential ...
Title: A dose-escalation and safety study of CID-103 followed by a randomized, open-label, parallel-arm multi-dose study ...
In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR); ...
The Division of Hematology-Oncology at Baylor College of Medicine is one of the largest and most comprehensive academic programs of its kind in the world. Faculty in the division provide care through ...
WOOD Grand Rapids on MSN
New UM Health-West cancer care building will serve as ‘one-stop shop’
Patients can now receive services at the University of Michigan Health-West's new Hematology and Cancer Care building in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback